Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer.
Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer. Clin Cancer Res. 2025 Aug 01; 31(15):3150-3159.
PMID: 40423530
Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207].
Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207]. Oral Oncol. 2025 Oct; 169:107510.
PMID: 40721367
A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell Carcinoma.
A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2025 May 30.
PMID: 40451439
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial.
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025 May 01; 11(5):492-501.
PMID: 40048190
No disease left behind.
No disease left behind. Oncotarget. 2025 Mar 13; 16:163-166.
PMID: 40079896
Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.
Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas. Oral Oncol. 2025 Apr; 163:107207.
PMID: 40043423
Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials.
Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials. Eur J Cancer. 2024 Sep; 209:114264.
PMID: 39106643
Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease.
Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease. J Clin Oncol. 2024 Oct 10; 42(29):3387-3391.
PMID: 39038267
Point/Counterpoint #2: Current Clinical Considerations With Nonoperative Management of Rectal Cancer.
Point/Counterpoint #2: Current Clinical Considerations With Nonoperative Management of Rectal Cancer. Cancer J. 2024 Jul-Aug 01; 30(4):256-263.
PMID: 39042777
SBRT for Liver Tumors: What the Interventional Radiologist Needs to Know.
SBRT for Liver Tumors: What the Interventional Radiologist Needs to Know. Semin Intervent Radiol. 2024 Feb; 41(1):1-10.
PMID: 38495259